ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Bellerophon Therapeutics Inc

Bellerophon Therapeutics Inc (BLPH)

0.1025
0.00
( 0.00% )
Updated: 20:00:00

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.1025
Bid
0.112
Ask
0.1139
Volume
-
0.00 Day's Range 0.00
0.076 52 Week Range 0.76
Market Cap
Previous Close
0.1025
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
12,232,648
Dividend Yield
-
PE Ratio
-0.06
Earnings Per Share (EPS)
-1.62
Revenue
-
Net Profit
-19.83M

About Bellerophon Therapeutics Inc

Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to ... Bellerophon Therapeutics Inc is a clinical-stage biotherapeutics company. The firm develops innovative products combining novel drugs and devices to treat cardiopulmonary diseases. It develops products under its INOpulse platform, which is an extension of the technology that is used in hospitals to deliver continuous-flow inhaled nitric oxide. The company products are aimed at the treatment of different kinds of pulmonary hypertension. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Bellerophon Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BLPH. The last closing price for Bellerophon Therapeutics was $0.10. Over the last year, Bellerophon Therapeutics shares have traded in a share price range of $ 0.076 to $ 0.76.

Bellerophon Therapeutics currently has 12,232,648 shares outstanding. The market capitalization of Bellerophon Therapeutics is $1.22 million. Bellerophon Therapeutics has a price to earnings ratio (PE ratio) of -0.06.

BLPH Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
52-0.6063-85.53893905190.70880.760.0763557990.30987777CS
156-5.0075-97.99412915855.1112.580.0765219933.0746262CS
260-0.5395-84.03426791280.64229.910.0764155564.50309963CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RGSRegis Corporation
$ 21.34
(320.91%)
42.41M
VLCNVolcon Inc
$ 6.3813
(64.47%)
26.14M
CPOPPop Culture Group Company Ltd
$ 1.6599
(44.34%)
33.1M
BTBTBit Digital Inc
$ 3.395
(39.71%)
36.53M
GRDIGRIID Infrastructure Inc
$ 1.90
(37.68%)
10.25M
HGASGlobal Gas Corporation
$ 0.41
(-58.16%)
21.1k
XAIRBeyond Air Inc
$ 0.6693
(-50.05%)
10.03M
ALLRAllarity Therapeutics Inc
$ 0.212649
(-33.34%)
28.22M
CRKNCrown Electrokinetics Corporation
$ 3.88
(-32.46%)
999.24k
NAASNaaS Technology Inc
$ 3.69
(-30.38%)
150.29k
NVDANVIDIA Corporation
$ 125.16
(5.97%)
331.02M
FFIEFaraday Future Intelligent Electric Inc
$ 0.2782
(-14.66%)
152.45M
GLYCGlycoMimetics Inc
$ 0.3314
(24.31%)
117.32M
SQQQProShares UltraPro Short QQQ
$ 8.4251
(-3.05%)
100.7M
LRHCLa Rosa Holdings Corporation
$ 1.74
(16.00%)
67.78M

BLPH Discussion

View Posts
delerious1 delerious1 7 months ago
Will this company ever start again...did the study find anything positive out of all their data?

Did they go as far as bankruptcy?
👍️0
Renee Renee 8 months ago
BLPH delisted from the Nasdaq to the OTC. ***PPS dropped 68% from .39 to .1235 on ~14 million volume.

https://otce.finra.org/otce/dailyList?viewType=Additions
🤢 1
willlbone willlbone 8 months ago
ten cents
👍️0
Awl416 Awl416 8 months ago
RIP…
🤢 1
maestro_of_Ihub maestro_of_Ihub 11 months ago
We all knew 33 cents was capitulation here! Congrats on those that waited and loaded with the maestro posse! Easy 10 banger here from those levels over next 36 months! Enjoy the ride, it will be bumpy but very profitable as always! 💪🏿😈
👍️0
Awl416 Awl416 11 months ago
Yikes
🤢 1
Law of Averages Law of Averages 11 months ago
This one is gonna run hard BB bands are pinched very tight.
👍️0
kingsransome kingsransome 1 year ago
failed trial
😔 1
Awl416 Awl416 1 year ago
What happened?
👍️0
delerious1 delerious1 1 year ago
NEWS

Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
May 15, 2023 16:50 ET | Source: Bellerophon Therapeutics, Inc.


Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023
WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2023.

“We are pleased with the progress we have made to date in 2023, highlighted by the completion of the blinded treatment phase of our ongoing pivotal Phase 3 REBUILD trial,” said Peter Fernandes, Bellerophon’s Chief Executive Officer. “We expect to report top-line results from the study in the middle of this year, a critical milestone for the Company. Importantly, following the recent license agreement with Baylor Bioscience and having successfully completed a $5 million equity financing, we are well-capitalized through this critical milestone.”

Clinical Program Highlights:

Fibrotic Interstitial Lung Disease (fILD)

REBUILD Phase 3 Study: The Company completed the blinded treatment phase of their pivotal Phase 3 REBUILD trial evaluating the safety and efficacy of INOpulse® for the treatment of patients with fILD and anticipates the availability of top-line results in mid-2023. A total of 145 fILD patients were enrolled and treated with either INOpulse at a dose of iNO45 or placebo. The Phase 3 program builds on positive top-line results from the Company’s previously reported Phase 2 studies for INOpulse® for the treatment of fILD which showed benefits in multiple cardiopulmonary parameters, including pulmonary vascular resistance and improvement in Moderate to Vigorous Physical Activity (MVPA) as measured by actigraphy after 16 weeks of chronic treatment. With a total of 145 patients enrolled, the study is powered >90%, (p-value of 0.01) for the primary endpoint of a change in MVPA measured by actigraphy. If approved, INOpulse would become the first therapy to treat a broad fILD population, including patients at low-, intermediate- and high-risk pulmonary hypertension.
Pulmonary Hypertension-Sarcoidosis (PH-Sarc)

Phase 2 Clinical Study: In December 2021, Bellerophon reported positive top-line data from the completed Phase 2 dose escalation study of INOpulse® evaluating the acute hemodynamic benefit of INOpulse® via right heart catheterization for the treatment of pulmonary hypertension associated with sarcoidosis (PH-Sarc). Based on the benefits demonstrated in hemodynamic parameters and favorable safety profile, Bellerophon designed and submitted to the FDA a proposed exploratory Phase 2 double-blinded placebo-controlled study to investigate the safety and efficacy of iNO45 dosed chronically for six months in patients with PH-Sarc. Subsequently, the Company received FDA clearance to conduct the study and Bellerophon is currently assessing the next steps for the study.

First Quarter Ended March 31, 2023, Financial Results:

Total licensing revenue for the three months ended March 31, 2023, was $5.6 million, which is related to the licensing agreement with Baylor BioSciences, Inc.

For the first quarter ended March 31, 2023, the Company reported net income of $2.8 million, or $0.27 per basic and diluted share, compared to a net loss of $5.6 million, or $(0.59) per basic and diluted share, in the first quarter ended March 31, 2022.

Research and development expenses for the first quarter ended March 31, 2023, were $2.6 million, compared to $4.4 million in the first quarter of 2022. The decrease was due to the completion of enrollment in the ongoing Phase 3 REBUILD trial in January 2023.

General and administrative expenses for the first quarter ended March 31, 2023, were $1.6 million, compared to $1.2 million in the first quarter of 2022. The increase was primarily due to an increase in general consulting costs and an increase in stock-based compensation.

Balance Sheet:

As of March 31, 2023, the Company had unrestricted cash and cash equivalents of $15.2 million, compared to unrestricted cash and cash equivalents of $6.9 million as of December 31, 2022. Bellerophon’s capital position as of March 31, 2023, is reflective of the transactions which closed in the first quarter of 2023. These transactions included $1.7 million net proceeds from the sale of the Company’s net operating losses and research and development credits under the State of New Jersey’s Technology Business Tax Certificate Transfer Program in January 2023, net proceeds of approximately $5 million related to the licensing agreement with Baylor BioSciences, and net proceeds of approximately $5 million from the registered direct offering, which closed in March 2023.

About Bellerophon

Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
👍️0
dinogreeves dinogreeves 1 year ago
Its got to be relatively low with those kind of spreads at times.
👍️0
eur06 eur06 1 year ago
Lol …one needs a flashlight to find the float .
BLPH
👍️0
dinogreeves dinogreeves 1 year ago
Cricket and frog.. lol
👍️0
eur06 eur06 1 year ago
It does jump like a cricket…lol
BLPH
👍️0
dinogreeves dinogreeves 1 year ago
This is must own ticker, a must. It has 5 times potential from here.
👍️0
eur06 eur06 1 year ago
That would be fantastic!
Thank you Dino.
BLPH
👍️0
dinogreeves dinogreeves 1 year ago
identical setup as what NVA*X did. I believe when the data comes out this will trade easily over 30 dollars.
👍️0
eur06 eur06 1 year ago
Great!
BLPH
👍️0
dinogreeves dinogreeves 1 year ago
Still here, with all my shares, going no where until the data is released, I decide from there.
👍️0
eur06 eur06 1 year ago
It’s happening!!!
BLPH
👍️0
eur06 eur06 1 year ago
Thank you Dino great to know all this!
BLPH
👍️0
dinogreeves dinogreeves 1 year ago
It's positive, yes Tang Capital took a passive position. This is all where it started with NVAX, with direct offering at $2.00 and they walked it up and did more again and again and finally hit 300 dollars, grant it covid era and totally different market, but this is cancer, I think this will do really well with positive data coming out by end of 2nd quarter.
👍️0
eur06 eur06 1 year ago
Positive or negative? Tia
I did some research found some passive stake by Tang Capital Partners 9.99% which is positive but not short term also they just had an offering dunno anymore, last thing chart seems ready for take off….but that is relative imo.
BLPH
👍️0
eur06 eur06 1 year ago
Negative? I don’t know about it then.
BLPH
👍️0
dinogreeves dinogreeves 1 year ago
Euro, I believe something is happening with BLPH.
👍️0
eur06 eur06 1 year ago
Thank you I didn't know going to add some.
BLPH
👍️0
dinogreeves dinogreeves 1 year ago
No, I mean data.
👍️0
eur06 eur06 1 year ago
Lol... you're likely correct and below 7 is a great opportunity to enter/add with such a tiny float... Btw do you mean earnings?
BLPH
👍️0
dinogreeves dinogreeves 1 year ago
Every time it wants to run, people sell. They are due for news between now and end of June. So people buy in the hopes of news after hours and when there is no news, they sell only to buy back the next day. That has been the pattern so far.
👍️0
eur06 eur06 1 year ago
About to do it !!!
BLPH
👍️0
Xunefox Xunefox 1 year ago
Cmon!!! pop!!
👍️0
dinogreeves dinogreeves 1 year ago
BLPH getting ready to pop. 9.40 blue skies above.
👍️0
dinogreeves dinogreeves 1 year ago
Futures are ripping hard, only a matter of time before BLPH does a double from there.
👍️0
dinogreeves dinogreeves 1 year ago
Watch this between Monday-Tuesday, something tells me, it is about to move fast into the teens.
👍️0
dinogreeves dinogreeves 1 year ago
BLPH will do what NVA*X did couple of years back.
👍️0
dinogreeves dinogreeves 1 year ago
BLPH is next weeks runner, runner.
👍️0
Awl416 Awl416 1 year ago
What a impressive run
👍️0
Invest-in-America Invest-in-America 1 year ago
BLPH: And THIS time around, EASY money all day long!!

👍️0
Awl416 Awl416 1 year ago
Wild
👍️0
Awl416 Awl416 1 year ago
News leak?
👍️0
Awl416 Awl416 1 year ago
8k out
👍️0
delerious1 delerious1 1 year ago
Nice to see this one green again...MBGA
👍️0
Invest-in-America Invest-in-America 1 year ago
BLPH: E-Turd will NOT accept orders on this right now! (What's happening here?? And it ain't no SKULL-&-CROSSBONES routine.)
👍️0
Invest-in-America Invest-in-America 1 year ago
BLPH: HUUUUUGE morn. gapper!!! (Be careful.)
👍️0
alchemytrader alchemytrader 1 year ago
RIP 3.40 chasers.
👍️0
makinezmoney makinezmoney 1 year ago
$BLPH: WOW..... now 2.50


Whatta runnerrrrrrrrrrrrrrrrrrrrr


Excellent call


GO $BLPH
👍️0
Welsh_Dragon Welsh_Dragon 1 year ago
Pre mkt 1.69 was a nice entry.

Where is everyone? This is getting shirts wrecked.
👍️0
tw0122 tw0122 1 year ago
Thursday King stock of the day 2.16
👍️0
delerious1 delerious1 2 years ago
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
09/27/2022 12:30 PM
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of >90% for the primary endpoint Independent Data Monitoring Committee agreed that the new targeted study size is appropriate Enrollment now expected to conclude in Q1 2023,
👍️0
delerious1 delerious1 2 years ago
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
08/15/2022 12:30 PM
WARREN, N.J. , Aug. 15, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial
👍️0

Your Recent History

Delayed Upgrade Clock